Search research articles
Contact Us
Filters
Showing results (11-20 of 30) with videos related to
Page
of 3
Sort By:
Biomaterials
|
October 3, 2018
Combinatorial cassettes to systematically evaluate tissue-engineered constructs in recipient mice
Subhadip Bodhak, Luis F de Castro, Sergei A Kuznetsov, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 29, 2021
Genotype-Phenotype Correlation in Fibrous Dysplasia/McCune-Albright Syndrome
Maria Zhadina, Kelly L Roszko, Raya E S Geels, et al.
The Journal of Clinical Investigation
|
March 21, 2023
Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source
Diana Ovejero, Zachary Michel, Christophe Cataisson, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 14, 2024
Safety and Efficacy of Moderate-Dose Denosumab in Fibrous Dysplasia: Observational Results from a Phase 2 Clinical Trial
Vivian Szymczuk, Ibrahim I Elbashir, Ramzy Ahmed, et al.
Endocrinology
|
February 7, 2009
Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes-related osteopenia
Daniel Lozano, Luis F de Castro, Sonia Dapía, et al.
Journal of Translational Medicine
|
October 29, 2013
IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand
Lucia Guerra-Menéndez, Maria C Sádaba, Juan E Puche, et al.
The Journal of Craniofacial Surgery
|
September 2, 2022
Malignant Sarcomatous Degeneration of Craniofacial Fibrous Dysplasia
Adnan S Hussaini, Daniel D Swanson, Peter L Nguy, et al.
Calcified Tissue International
|
June 20, 2020
Successful Intravascular Treatment of an Intraosseous Arteriovenous Fistula in Fibrous Dysplasia
Kristen S Pan, Luis F de Castro, Kelly L Roszko, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 2, 2026
A phase 2 trial of burosumab for treatment of fibroblast growth factor-23 mediated hypophosphatemia in children and adults with fibrous dysplasia
Olivia de Jong, Zubeyir Hasan Gun, Afua Asante-Otoo, et al.
Bone Research
|
April 26, 2026
A phase 2 trial of burosumab for treatment of fibroblast growth factor-23-mediated hypophosphatemia in children and adults with fibrous dysplasia
Olivia de Jong, Zubeyir Hasan Gun, Afua Asante-Otoo, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 30) with videos related to
Sort By:
Page
of 3
Biomaterials
|
October 3, 2018
Combinatorial cassettes to systematically evaluate tissue-engineered constructs in recipient mice
Subhadip Bodhak, Luis F de Castro, Sergei A Kuznetsov, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 29, 2021
Genotype-Phenotype Correlation in Fibrous Dysplasia/McCune-Albright Syndrome
Maria Zhadina, Kelly L Roszko, Raya E S Geels, et al.
The Journal of Clinical Investigation
|
March 21, 2023
Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source
Diana Ovejero, Zachary Michel, Christophe Cataisson, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 14, 2024
Safety and Efficacy of Moderate-Dose Denosumab in Fibrous Dysplasia: Observational Results from a Phase 2 Clinical Trial
Vivian Szymczuk, Ibrahim I Elbashir, Ramzy Ahmed, et al.
Endocrinology
|
February 7, 2009
Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes-related osteopenia
Daniel Lozano, Luis F de Castro, Sonia Dapía, et al.
Journal of Translational Medicine
|
October 29, 2013
IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand
Lucia Guerra-Menéndez, Maria C Sádaba, Juan E Puche, et al.
The Journal of Craniofacial Surgery
|
September 2, 2022
Malignant Sarcomatous Degeneration of Craniofacial Fibrous Dysplasia
Adnan S Hussaini, Daniel D Swanson, Peter L Nguy, et al.
Calcified Tissue International
|
June 20, 2020
Successful Intravascular Treatment of an Intraosseous Arteriovenous Fistula in Fibrous Dysplasia
Kristen S Pan, Luis F de Castro, Kelly L Roszko, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 2, 2026
A phase 2 trial of burosumab for treatment of fibroblast growth factor-23 mediated hypophosphatemia in children and adults with fibrous dysplasia
Olivia de Jong, Zubeyir Hasan Gun, Afua Asante-Otoo, et al.
Bone Research
|
April 26, 2026
A phase 2 trial of burosumab for treatment of fibroblast growth factor-23-mediated hypophosphatemia in children and adults with fibrous dysplasia
Olivia de Jong, Zubeyir Hasan Gun, Afua Asante-Otoo, et al.
Page
of 3